Article Data

  • Views 562
  • Dowloads 135

Original Research

Open Access

Effects of zoledronic acid and exemestane combination therapy on immune function, sex hormones, bone markers, and clinical efficacy in hormone receptor-positive breast cancer patients

  • Ruipeng Zhao1,*,†,
  • Cheng Chen1,†
  • Linlin Zhen1,*,

1Department of Thyroid and Breast Surgery, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, 223000 Huai’an, Jiangsu, China

DOI: 10.22514/ejgo.2024.029 Vol.45,Issue 2,April 2024 pp.66-74

Submitted: 06 July 2023 Accepted: 20 September 2023

Published: 15 April 2024

*Corresponding Author(s): Ruipeng Zhao E-mail: Simu1027@sina.com
*Corresponding Author(s): Linlin Zhen E-mail: rpzhao@hotmail.com

† These authors contributed equally.

Abstract

The effect of treatment by zoledronic acid combined with exemestane was explored pertaining to the immune function, sex hormones, bone markers, and clinical efficacy in hormone receptor-positive breast cancer patients. Eighty elderly patients with hormone receptor-positive breast cancer were selected as the study subjects who were clinically admitted from December 2016 to December 2021. The study and control groups had 40 cases each and were analyzed according to different treatment methods. The control group received exemestane treatment, while the study group was treated with a combination of zoledronic acid and exemestane. The immune functions, sex hormones, bone markers, clinical efficacy, adverse reactions, life quality scores, serum calcium, and vascular endothelial growth factor for the two groups were analyzed and compared. The cluster of differentiation (CD), E2, P and T levels were lower than those of the control after treatment, and the difference was statistically significant, p < 0.05. Similar effect was observed in β-Cross Laps, serum calcium levels and N-terminal propeptide of type 1precollagen (PINP) levels. Physiological and psychological scores were higher than the control after treatment, and difference was statistically significant, p < 0.05. The incidence of adverse reactions was 20.00% for the study group while 42.50% for control, and the difference was statistically significant, p < 0.05. We conclude that Zoledronic acid combined with exemestane in treating hormone receptor-positive breast cancer patients could improve clinical efficacy, immune function, bone metabolism, quality of life, regulate the sex hormones, and possess drug safety.


Keywords

Zoledronic acid; Exemestane; Breast cancer; Clinical efficacy; Immunologic function


Cite and Share

Ruipeng Zhao,Cheng Chen,Linlin Zhen. Effects of zoledronic acid and exemestane combination therapy on immune function, sex hormones, bone markers, and clinical efficacy in hormone receptor-positive breast cancer patients. European Journal of Gynaecological Oncology. 2024. 45(2);66-74.

References

[1] Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clinical Cancer Research. 2020; 26: 5172–5177.

[2] Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, et al. Phase I/II trial of Exemestane, Ribociclib, and Everolimus in women with HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research. 2021; 27: 4177–4185.

[3] Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. Journal of Clinical Oncology. 2023; 41: 1376–1382.

[4] Makhlin I, McAndrew NP, Wileyto EP, Clark AS, Holmes R, Bottalico LN, et al. Ruxolitinib and exemestane for estrogen receptor-positive, aromatase inhibitor resistant advanced breast cancer. NPJ Breast Cancer. 2022; 8: 122.

[5] Ishikawa T. Differences between zoledronic acid and denosumab for breast cancer treatment. Journal of Bone and Mineral Metabolism. 2023; 41: 301–306.

[6] Sheweita SA, Ammar RG, Sabra SA, Sultan AS. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences. 2021; 16: 112–120.

[7] Sorscher S. Duration and dose of adjuvant zoledronic acid for treatment of early breast cancer. JAMA Oncology. 2022; 8: 171.

[8] Wang Q, Guo G, Ruan Z, Cao H, Guo Y, Bai L, et al. Safety and efficacy of long-term zoledronic acid in advanced breast cancer with bone metastasis in South China. Journal of Oncology. 2020; 2020: 5670601.

[9] Rahimian L, Kalantari Khandani B, Nemati M, Hoseini-Shahrestanak S, Aminizadeh N, Jafarzadeh A. Reduced expression of natural killer cell-related activating receptors by peripheral blood mononuclear cells from patients with breast cancer and their improvement by zoledronic acid. Asian Pacific Journal of Cancer Prevention. 2022; 23: 1661–1669.

[10] Friedl TWP, Janni W, Rack B. Duration and dose of adjuvant zoledronic acid for treatment of early breast cancer—reply. JAMA Oncology. 2022; 8: 171–172.

[11] Kim JW, Lee S, Kim HS, Choi YJ, Yoo J, Park KU, et al. Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). Cytokine. 2021; 142: 155487.

[12] Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, et al. Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer. Journal of Bone and Mineral Metabolism. 2022; 40: 998–1006.

[13] Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, et al. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid. NPJ Breast Cancer. 2021; 7: 113.

[14] Buch-Larsen K, Jørgensen NR, Jensen LT, Andersson M, Schwarz P. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study. Scandinavian Journal of Clinical and Laboratory Investigation. 2021; 81: 425–431.

[15] Crocamo S, Binato R, Dos Santos EC, de Paula B, Abdelhay E. Translational results of Zo-NAnTax: a phase II trial of neoadjuvant zoledronic acid in HER2-positive breast cancer. International Journal of Molecular Sciences. 2022; 23: 15515.

[16] Jallouk AP, Paravastu S, Weilbaecher K, Aft RL. Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer. Breast Cancer Research and Treatment. 2021; 187: 135–144.

[17] Huang X, Liu Y, Lin S, Wang H, Deng Y, Rao X, et al. Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis. International Journal for Quality in Health Care. 2023; 35: mzad016.

[18] Liu M, Qian S, Wu J, Xiao J, Zeng X. The effects of neoadjuvant zoledronic acid in breast cancer patients: a meta-analysis of randomized controlled trials. Asian Journal of Surgery. 2023; 46: 4124–4130.

[19] Matsuura K, Saeki T, Takahashi T, Torigoe T, Watarai K, Osaki A, et al. Bilateral femoral head osteonecrosis in a patient with metastatic breast cancer receiving long-term zoledronic acid treatment: a case report. Molecular and Clinical Oncology. 2021; 15: 166.

[20] Chacko G, Kota S, Kumar S, Ohri N, Omene C, Ganesan S, et al. Uveitis, is a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer. Anti-Cancer Drugs. 2023; 34: 592–594.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top